GlassScriptPhysician profile
Delaina Evans
NPI 1417682824
$1,352.15
in general payments reported to CMS, 2019-2025
22 companies · $233 in 2025
The $233 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $218 · 2023: $320 · 2024: $581 · 2025: $233.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,134.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,134.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $405.42 | 2023-2025 | |
| Novo Nordisk INC | $131.43 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $114.70 | 2022-2025 | Shingrix, Arexvy, Bexsero |
| Lilly USA, LLC | $103.56 | 2023-2024 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $86.93 | 2022-2024 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $61.05 | 2024-2025 | Repatha, Otezla, Repatha |
| Genzyme Corporation | $46.02 | 2022 | |
| Kaleo, INC. | $40.16 | 2022 | |
| Exact Sciences Corporation | $37.32 | 2023-2024 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $36.87 | 2023 | Quviviq |
| Pfizer INC. | $36.18 | 2024 | |
| Novartis Pharmaceuticals Corporation | $33.87 | 2024 | |
| Merck Sharp & Dohme LLC | $29.97 | 2023 | Belsomra, Steglatro, Verquvo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.29 | 2024 | Xifaxan |
| Regeneron Healthcare Solutions, INC. | $27.20 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $25.68 | 2023 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $19.94 | 2023 | Trintellix |
| Exeltis, USA INC. | $18.43 | 2023 | Slynd |
| Optinose US, INC. | $17.73 | 2022 | |
| Phathom Pharmaceuticals, INC. | $16.84 | 2023 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $16.84 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.72 | 2024 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Delaina Evans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.